Novo plows ahead in Russia; NICE nod to Xarelto; India's Biocon sees profits fall; $31M payday for Auxilium execs;

@FiercePharma: ICYMI yesterday: Pfizer wins recommendation for Prevenar expansion in Europe. Story | Follow @FiercePharma

@EricPFierce: UAE-based Gulf Pharmaceuticals intends to build a $50M insulin plant in Ethiopia. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Ex-Sanofi chief Viehbacher makes a $5M-plus severance deal. Article | Follow @CarlyHFierce

> Novo Nordisk ($NVO) says it is continuing with a plant in Russia, despite economic issues in the country, as it prepares itself for the future. Story

> The U.K. cost watchdog NICE has issued final guidance recommending Bayer blood thinner Xarelto to treat blood clots in patients who have had a heart attack. Release

> India's Biocon reported a 13% decline in net profit for the last quarter and says it will sell a 10% to 15% stake in its Syngene research unit. Report

> EU evaluators have recommended expanding approval of Novo Nordisk blood cancer treatment Jakavi to include polycythemia vera, a chronic incurable blood cancer. Report

> Hospira ($HSP) is recalling one lot of saline solution after human hair was found in a single unit. Report

Medical Device News

@FierceMedDev: Roche's Ventana inches closer to FDA approval for lung cancer companion Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Welch Allyn buys eye exam provider, signaling move into services. Article | Follow @VarunSaxena2

@EmilyWFierce: Au revoir, Weber; Bonjour, Bohuon? FiercePharma article | Follow @EmilyWFierce

> Profit down 12% at Intuitive Surgical, but procedure volume up due to strength abroad and in general surgery. More

> France's bioMérieux and Astute Medical join forces on acute kidney injury test. Article

Biotech News

@FierceBiotech: EuroBiotech: EU IPOs obliterate recent highs, U.K. VC funding tops $700M, Woodford backs microbiome play. Report | Follow @FierceBiotech

@JohnCFierce: Interviewed the CEO at the new CAR-T player. Their CSO also worked on Bellicum program. Story | Follow @JohnCFierce

@DamianFierce: $MDCO's Clive Meanwell has by far the best name among biopharma CEOs. At least until someone appoints Guy Smiley. | Follow @DamianFierce

> The Medicines Co.'s FDA-rejected cardio drug finds EU success. Report

> GlaxoSmithKline's Ebola vaccine rolls into Phase III as outbreak simmers. Article

And Finally... Half a dozen execs at Auxilium Pharmaceuticals will share $31 million after cashing in stock options and awards following the completion of the buyout by Endo International ($ENDP), including CEO Adrian Adams, who will get $15.5 million alone. Story

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.